Storia in 2 fonti

Gedeon Richter, Hetero Labs ink global pact for Semaglutide injection

Gedeon Richter and Hetero Labs form a global partnership to develop and commercialize Semaglutide Injection, enhancing diabetes treatment access.

Raccontata da

thehindubusinessline.com

economictimes.indiatimes.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo2 g fa

Gedeon Richter, Hetero Labs ink global pact for Semaglutide injection

Gedeon Richter and Hetero Labs form a global partnership to develop and commercialize Semaglutide Injection, enhancing diabetes treatment access.

originale

economictimes.indiatimes.com2 g fa

Hetero partners with Richter to develop, market Semaglutide injection globally

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to expand global access to diabetes…

Leggi questa versione →

Timeline cronologica

mercoledì 10 giugno 2026·thehindubusinessline.com
Gedeon Richter, Hetero Labs ink global pact for Semaglutide injection
Gedeon Richter and Hetero Labs form a global partnership to develop and commercialize Semaglutide Injection, enhancing diabetes treatment access.
mercoledì 10 giugno 2026·economictimes.indiatimes.com
Hetero partners with Richter to develop, market Semaglutide injection globally
Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic of Ozempic. This collaboration aims to…